Literature DB >> 24070130

Neural stem/progenitor cell transplantation for cortical visual impairment in neonatal brain injured patients.

Zuo Luan, Suqing Qu, Kan Du, Weipeng Liu, Yinxiang Yang, Zhaoyan Wang, Ying Cui, Qingan Du.   

Abstract

The purpose of this study was to investigate the clinical efficacy of neural stem/progenitor cell (NS/PC) transplantation to treat severe cortical visual impairment (CVI), a sequela of neonatal brain injury. Fifty-two patients with cerebral injury and CVI were randomly divided into two groups: the treatment group (n = 25, with the median age of 18 months) and the control group (n = 27, with the median age of 19.5 months). The treatment group received intracerebroventricular transplantation of human NS/PCs and rehabilitation training. The control group received rehabilitation only. The visual function was assessed by Holt's method at various time points after transplantation. One in five patients with fundus abnormalities accompanied by blindness regained light perception. The visual functions of 75% of the patients with normal fundus were improved by one level or more in a 2-year follow-up. The median efficacy appeared 60 days posttransplantation. The total effective rate of cell transplantation on visual improvement was 64% (16 patients of 25), among which one blind patient regained light perception, five (31.2%) CVI patients improved by one level, and 10 (62.5%) improved by more than one level. Functional magnetic resonance imaging (fMRI) in a subpopulation of patients showed enhanced signals in the occipital lobe, visual pathway, and apical lobe after transplantation. In the control group, four patients with fundus abnormalities showed no improvement. Nine of 23 CVI patients with normal fundus improved visual function by more than one level. At the 2-year follow-up, no blind patients showed visual improvement. The total effective rate was 33.33% (9 of 27 patients). Among those showing visual improvement in the control group, six patients (66.67%) improved by one level, and three (33.33%) by more than one level. The median efficacy occurred in 365 days. Human NS/PC transplantation is effective to treat patients with severe CVI after neonatal brain injury. Compared with the traditional rehabilitation training, cell transplantation showed not only earlier visual improvement but also higher improvement rates and degrees. This article is published as part of the International Association of Neurorestoratology (IANR) supplement issue of Cell Transplantation.

Entities:  

Mesh:

Year:  2013        PMID: 24070130     DOI: 10.3727/096368913X672163

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  7 in total

1.  Human Neural Stem Cells with GDNF Site-Specific Integration at AAVS1 by Using AAV Vectors Retained Their Stemness.

Authors:  Jinju Zhang; Xiaomei Liu; Yun Zhang; Zuo Luan; Yinxiang Yang; Zhaoyan Wang; Chun Zhang
Journal:  Neurochem Res       Date:  2018-02-12       Impact factor: 3.996

Review 2.  Stem Cell Therapy for the Central Nervous System in Lysosomal Storage Diseases.

Authors:  Faez Siddiqi; John H Wolfe
Journal:  Hum Gene Ther       Date:  2016-07-13       Impact factor: 5.695

Review 3.  Pathophysiology Associated with Traumatic Brain Injury: Current Treatments and Potential Novel Therapeutics.

Authors:  Matthew L Pearn; Ingrid R Niesman; Junji Egawa; Atsushi Sawada; Angels Almenar-Queralt; Sameer B Shah; Josh L Duckworth; Brian P Head
Journal:  Cell Mol Neurobiol       Date:  2016-07-06       Impact factor: 5.046

4.  Study on the Safety of Human Oligodendrocyte Precursor Cell Transplantation in Young Animals and Its Efficacy on Myelination.

Authors:  Haipeng Zhou; Siliang Lu; Ke Li; Yinxiang Yang; Caiyan Hu; Zhaoyan Wang; Qian Wang; Ying He; Xiaohua Wang; Dou Ye; Qian Guan; Jing Zang; Chang Liu; Suqing Qu; Zuo Luan
Journal:  Stem Cells Dev       Date:  2021-04-29       Impact factor: 3.272

Review 5.  Traumatic Brain Injury: Current Treatment Strategies and Future Endeavors.

Authors:  Michael Galgano; Gentian Toshkezi; Xuecheng Qiu; Thomas Russell; Lawrence Chin; Li-Ru Zhao
Journal:  Cell Transplant       Date:  2017-07       Impact factor: 4.064

Review 6.  Stem cells: a promising candidate to treat neurological disorders.

Authors:  Chang-Geng Song; Yi-Zhe Zhang; Hai-Ning Wu; Xiu-Li Cao; Chen-Jun Guo; Yong-Qiang Li; Min-Hua Zheng; Hua Han
Journal:  Neural Regen Res       Date:  2018-07       Impact factor: 5.135

Review 7.  Development of a core outcome set for evaluative research into paediatric cerebral visual impairment (CVI), in the UK and Eire.

Authors:  Anna Pease; Trudy Goodenough; Cath Borwick; Rose Watanabe; Christopher Morris; Cathy Williams
Journal:  BMJ Open       Date:  2021-09-29       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.